-+ 0.00%
-+ 0.00%
-+ 0.00%

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Barchart·07/29/2026 06:05:00
Listen to the news

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.